Envudeucitinib

About Alumis

Alumis is advancing a late-stage portfolio of targeted therapies designed to transform treatment for immune-mediated diseases. The company leverages a proprietary data analytics platform integrating genetic, genomic, proteomic, and clinical insights to drive smarter therapeutic development. With a seasoned leadership team and a lead asset in Phase 3 for psoriasis, Alumis aims to deliver optimized therapies that help millions worldwide live healthier, fuller lives.

Therapeutic Areas

Other Moderate-to-Severe Plaque Psoriasis Drugs